NAD+, Sirtuins, and Cardiovascular Disease

E-ISSN： 1873-4286|15|1|110-117

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.15, Iss.1, 2009-01, pp. : 110-117

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of NAD+ Dependent Histone Deacetylases (sirtuins) in Ageing

Current Drug Targets, Vol. 7, Iss. 11, 2006-11 ,pp. : 1553-1560

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of NAD+ Dependent Histone Deacetylases (Sirtuins)

Current Pharmaceutical Design, Vol. 14, Iss. 6, 2008-02 ,pp. : 562-573

Bentham Science Publishers

Access to resources Recommend Favorite

Insulin Resistance, Oxidative Stress and Cardiovascular Complications: Role of Sirtuins

Current Pharmaceutical Design, Vol. 19, Iss. 32, 2013-10 ,pp. : 5663-5677

Bentham Science Publishers

Access to resources Recommend Favorite

Alzheimers Disease, Ceramide, Visfatin and NAD

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 7, Iss. 6, 2008-12 ,pp. : 492-498

Bentham Science Publishers

Access to resources Recommend Favorite

The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases

By Cai H. Griendling K.K. Harrison D.G.

Trends in Pharmacological Sciences, Vol. 24, Iss. 9, 2003-09 ,pp. : 471-478

Elsevier

Access to resources Recommend Favorite